Ferric Derisomaltose
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Ferric Derisomaltose
- Ferric Derisomaltose: From Iron Deficiency Anaemia to Severe Nonproliferative Diabetic Retinopathy
Ferric Derisomaltose: From Iron Deficiency Anaemia to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Ferric derisomaltose (DrugBank DB15617) is an intravenous iron replacement product, with its established use in iron deficiency anaemia evidenced by two completed Phase 3 trials (FERWON-IDA, FERWON-NEPHRO) in this evidence pack. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this specific prediction currently has 0 clinical trials and 0 publications supporting it — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency anaemia (inferred from clinical trial evidence in this pack; not separately confirmed by regulatory licensing data) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for ferric derisomaltose (flagged as a High-severity data gap). Based on known information, ferric derisomaltose is an intravenous iron carbohydrate complex used to correct iron deficiency, and this use has been demonstrated in large Phase 3 trials (FERWON-IDA, n=1512; FERWON-NEPHRO, n=1538).
The proposed link to diabetic retinopathy rests on an “anaemia–hypoxia” hypothesis: iron deficiency anaemia reduces blood oxygen-carrying capacity, which is a recognised contributor to retinal ischaemia and can worsen diabetic retinopathy. A closely related, less severe prediction — plain “diabetic retinopathy” (TxGNN score 96.73%, evidence level L4) — has some indirect supporting evidence from the same two IDA trials, though neither trial measured retinal outcomes and both are graded low relevance (Grade C).
For the specific prediction in this report, severe nonproliferative diabetic retinopathy, no clinical trials or literature have been identified at all. The mechanistic rationale is plausible by extension from the milder subtype, but it is currently unverified and should be treated as a hypothesis generated purely by the model score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Ferric derisomaltose is not marketed in Australia; there are no ARTG entries currently registered for this product.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Note: TFDA/PI warnings and contraindications for this drug could not be retrieved (Blocking data gap) — this must be resolved before any initial safety screening (S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction (severe nonproliferative diabetic retinopathy) has no clinical trial or literature support — it is an L5, model-score-only signal at decision stage S0. The mechanistic rationale is plausible but entirely inferential.
To proceed, the following is needed:
- Product Information (PI) / TFDA warnings and contraindications (currently a Blocking gap)
- Mechanism of action data for ferric derisomaltose
- Dedicated studies evaluating iron repletion and retinal outcomes in diabetic retinopathy patients
- Consider tracking the related “diabetic retinopathy” (non-severe subtype) prediction instead, which has stronger evidence (L4, decision stage S1, two Phase 3 trials) and may be a more tractable research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.